OvaScience to Present at the 25th Annual Credit Suisse Healthcare Conference

WALTHAM, Mass.–(BUSINESS WIRE)–OvaScience℠ (NASDAQ: OVAS), a global fertility company focused on the
discovery, development and commercialization of new treatment options,
today announced that Harald Stock, Ph.D., President and Chief Executive
Officer, will present a corporate overview at the 25th Annual
Credit Suisse Healthcare Conference on Monday, November 7, 2016 at 8:30
a.m. MT (10:30 a.m. ET) at The Phoenician in Scottsdale, Arizona.

A live audio webcast of the presentation can be accessed by visiting the
investor section of the company’s website at www.ovascience.com.
A replay of the webcast will be achieved on the OvaScience website for
30 days following the presentation.

About OvaScience

OvaScience℠ (NASDAQ: OVAS) is a global fertility company dedicated to
improving treatment options for women around the world. OvaScience is
discovering, developing and commercializing new fertility treatments
because we believe women deserve more options. Each OvaScience treatment
is based on the Company’s proprietary technology platform that leverages
the breakthrough discovery of egg precursor (EggPC℠) cells – immature
egg cells found inside the protective ovarian lining. The AUGMENT℠
treatment, a fertility option specifically designed to improve egg
health, is available in certain IVF clinics in select international
regions. OvaScience is developing the OvaPrime℠ treatment, which could
increase a woman’s egg reserve, and the OvaTure℠ treatment, a potential
next-generation IVF treatment that could help a woman produce healthy,
young, fertilizable eggs without hormone injections. OvaScience
treatments are not available in the U.S. For more information, visit www.ovascience.com
and www.augmenttreatment.com
with us on Twitter and Facebook.

Contacts

OvaScience, Inc.
Jennifer Viera, 617-420-8748
jviera@ovascience.com